Fecal microbiota transplantation (FMT) is gaining traction as a treatment for various conditions, particularly for resistant C. diff infections. While currently FDA-approved only for C. diff, promising research is underway for its use in inflammatory bowel diseases like ulcerative colitis and Crohn's disease. With new FDA-approved FMT products available, the process is becoming more streamlined, offering hope for patients seeking alternative treatments.
